MarketCap
Facebook
X
Telegram
Adagene DSO | ADAG
DSO Jährlich Adagene
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 58.9 | 53.8 | 125 | 182 | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 182 | 53.8 | 105 |
DSO anderer Aktien in der Pharmaeinzelhändler
| Name | DSO | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Seer
SEER
|
47.3 | $ 1.61 | -0.31 % | $ 88.9 M |  USA |
 |
Stoke Therapeutics
STOK
|
7.52 | $ 27.75 | 1.98 % | $ 1.64 B | USA |
 |
Sutro Biopharma
STRO
|
22.4 | $ 10.25 | 0.79 % | $ 87.1 M | USA |
 |
Soligenix
SNGX
|
87.4 | $ 0.32 | 0.37 % | $ 1.66 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
823 | $ 43.19 | 1.85 % | $ 49.5 B |  Israel |
 |
China SXT Pharmaceuticals
SXTC
|
358 | $ 2.96 | 2.78 % | $ 2.01 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
79.3 | $ 20.83 | -0.38 % | $ 32.9 B |  Japan |
 |
Supernus Pharmaceuticals
SUPN
|
83.7 | $ 29.29 | 1.88 % | $ 1.65 B | USA |
 |
Galapagos NV
GLPG
|
56.5 | - | - | $ 1.83 B |  Belgium |
 |
Savara
SVRA
|
2.41 K | $ 5.03 | 2.24 % | $ 1.12 B | USA |
 |
Teligent, Inc.
TLGT
|
90.7 | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
169 | - | - | $ 2.91 B | USA |
 |
TG Therapeutics
TGTX
|
129 | $ 65.76 | 2.33 % | $ 9.49 B | USA |
 |
Aphria Inc.
APHA
|
55.2 | - | -0.45 % | $ 4.87 B |  Canada |
 |
Chiasma, Inc.
CHMA
|
178 | - | -6.00 % | $ 238 M | USA |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
45.6 | - | - | $ 376 M | USA |
 |
Cerecor Inc.
CERC
|
239 | - | -1.68 % | $ 283 M | USA |
 |
Auris Medical Holding Ltd.
EARS
|
147 | - | -1.77 % | $ 39.2 M |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
80.1 | - | 0.34 % | $ 2.98 B | USA |
 |
ERYTECH Pharma S.A.
ERYP
|
52.8 | - | 1.3 % | $ 27.7 M |  France |
 |
GW Pharmaceuticals plc
GWPH
|
49.3 | - | - | $ 6.81 B |  Britain |
 |
Kadmon Holdings, Inc.
KDMN
|
30.6 | - | - | $ 1.7 B | USA |
 |
Liminal BioSciences
LMNL
|
429 | - | - | $ 256 M | Canada |
 |
XBiotech
XBIT
|
40.8 | $ 1.95 | -1.02 % | $ 59.5 M | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
150 | - | -2.54 % | $ 57.2 M | USA |
 |
Osmotica Pharmaceuticals plc
OSMT
|
54.2 | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
0.0395 | - | - | $ 1.77 B | USA |
 |
Xenetic Biosciences
XBIO
|
365 | $ 1.87 | 3.68 % | $ 3.18 M | USA |
 |
Translate Bio, Inc.
TBIO
|
69.9 | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
2.34 K | - | - | $ 1.94 B | Canada |
 |
Acceleron Pharma Inc.
XLRN
|
42.2 | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
75.3 | - | 0.52 % | $ 821 M |  Danmark |
 |
Zogenix, Inc.
ZGNX
|
102 | - | -4.97 % | $ 664 M | USA |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
4.66 K | - | -7.58 % | $ 264 M | USA |
 |
Vanda Pharmaceuticals
VNDA
|
85.9 | $ 4.17 | 2.08 % | $ 246 M | USA |